|
| 37528179 | Correction: Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries. | Eye (Lond) | 2024 |
| 36526863 | Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review. | Eye (Lond) | 2023 |
| 37326222 | Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus. | Curr Opin Ophthalmol | 2023 |
| 37326216 | The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus. | Curr Opin Ophthalmol | 2023 |
| 37081576 | The MATE trial: a multicentre, mixed-methodology, pilot, randomised controlled trial in neovascular age-related macular degeneration. | Pilot Feasibility Stud | 2023 |
| 37280350 | Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries. | Eye (Lond) | 2023 |
| 37109349 | A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1. | J Clin Med | 2023 |
| 36973337 | Assessing the structure of the posterior visual pathway in bilateral macular degeneration. | Sci Rep | 2023 |
| 33971353 | Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER. | Ophthalmol Retina | 2022 |
| 35622355 | Cortical Atrophy Predicts Visual Performance in Long-Term Central Retinal Disease; GCL, pRNFL and Cortical Thickness Are Key Biomarkers. | Invest Ophthalmol Vis Sci | 2022 |
| 35314774 | The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice. | Eye (Lond) | 2022 |
| 34974541 | An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. | Eye (Lond) | 2022 |
| 35278204 | An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. | Ophthalmol Ther | 2022 |
| 34968756 | Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid. | Ophthalmol Retina | 2022 |
| 34340976 | Early detection of neovascular age-related macular degeneration: an economic evaluation based on data from the EDNA study. | Br J Ophthalmol | 2022 |
| 32532760 | Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser. | Br J Ophthalmol | 2021 |
| 34529124 | Assessing functional reorganization in visual cortex with simulated retinal lesions. | Brain Struct Funct | 2021 |
| 34192155 | Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. | BMJ Open Ophthalmol | 2021 |
| 34329651 | Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study. | Ophthalmology | 2021 |
| 34081099 | Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration. | JAMA Ophthalmol | 2021 |
| 33007521 | Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment. | Ophthalmol Retina | 2021 |
| 32962992 | Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections. | Br J Ophthalmol | 2021 |
| 31383649 | Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. | Br J Ophthalmol | 2020 |
| 31900438 | Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. | Eye (Lond) | 2020 |
| 31743912 | Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. | Ophthalmologica | 2020 |
| 32770474 | Demographic and Clinical Factors that Influence the Visual Response to Anti-Vascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration: A Systematic Review. | Ophthalmol Ther | 2020 |
| 32699378 | Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. | Eye (Lond) | 2020 |
| 32546938 | Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery. | Clin Ophthalmol | 2020 |
| 32270607 | Use of biologics in non-infectious uveitis: the situation in northern England. | Intern Med J | 2020 |
| 30459469 | Ophthalmology research in the UK's National Health Service: the structure and performance of the NIHR's Ophthalmology research portfolio. | Eye (Lond) | 2019 |
| 31800962 | Following the Status of Visual Cortex Over Time in Patients With Macular Degeneration Reveals Atrophy of Visually Deprived Brain Regions. | Invest Ophthalmol Vis Sci | 2019 |
| 31179389 | Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema. | BMJ Open Ophthalmol | 2019 |
| 30926932 | Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. | Eye (Lond) | 2019 |
| 31036317 | Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. | Lancet Haematol | 2019 |
| 29852030 | Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. | JAMA Ophthalmol | 2018 |
| 30175386 | The role of OCT-A in retinal disease management. | Graefes Arch Clin Exp Ophthalmol | 2018 |
| 28806779 | A mutation in Nischarin causes otitis media via LIMK1 and NF-κB pathways. | PLoS Genet | 2017 |
| 28181178 | The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis. | Drugs | 2017 |
| 28490797 | Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. | Eye (Lond) | 2017 |
| 29184385 | Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. | Clin Ophthalmol | 2017 |
| 27784021 | Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials. | Ophthalmologica | 2016 |
| 26645222 | Non-Infectious Uveitis: Optimising the Therapeutic Response. | Drugs | 2016 |
| 25488611 | Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab. | Acta Ophthalmol | 2015 |
| 26446737 | Defining response to anti-VEGF therapies in neovascular AMD. | Eye (Lond) | 2015 |
| 26156564 | Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. | Eye (Lond) | 2015 |
| 26126503 | Patient attitudes towards prenatal diagnostic testing for inherited retinal disease. | Prenat Diagn | 2015 |
| 26150052 | Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. | Ophthalmology | 2015 |
| 26039355 | Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study. | PLoS One | 2015 |
| 25893795 | A missense variant in CST3 exerts a recessive effect on susceptibility to age-related macular degeneration resembling its association with Alzheimer's disease. | Hum Genet | 2015 |
| 25416083 | Roux-en-Y gastric bypass could slow progression of retinopathy in type 2 diabetes: a pilot study. | Obes Surg | 2015 |